Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Pharma Univ. VISTA compound B3
- Development stage
- Preclinical
- Lead developer
- China Pharmaceutical University
- Modality
- Small Molecules
01
Overview
China Pharma Univ. VISTA compound B3: sourced facts only. name: "B3 showed the strongest binding affinity to the VISTA protein with a KD value of 0.452 ± 0.12 μM." [PMID:40014385]; target: "B3 showed the strongest binding affinity to the VISTA protein with a KD value of 0.452 ± 0.12 μM." [PMID:40014385]; developer: "School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China." [PMID:40014385]; modality: "These results suggest that compound B3 is a promising VISTA small molecule inhibitor and degrader worthy of further development as an antitumor agent." [PMID:40014385]; stage: "Moreover, compound B3 significantly inhibited tumor growth in a CT26 colon cancer model." [PMID:40014385]
02
Targets
VISTA
Beyond the preview
Go deeper on China Pharma Univ. VISTA compound B3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Pharma Univ. VISTA compound B3.